Search results
These Inhalers No Longer Cost More Than $35 Per Month
Verywell Health via Yahoo News· 1 month agoGrace Cary / Getty Images Fact checked by Nick Blackmer Key Takeaways Three major pharmaceutical...
Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results
GuruFocus.com via Yahoo Finance· 2 months agoRevenue: Innoviva Inc (NASDAQ:INVA) reported a 35% year-over-year increase in net product revenues...
GSK Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 2 days agoWe expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
Zacks via Yahoo Finance· 1 month agoGSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month...
Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
Zacks via Yahoo Finance· 2 years agoTheravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The...